Effects of a Isokinetic Exercise in Women With Fibromyalgia

Effects of a Microdoses Isokinetic Exercise Protocol in Women With Fibromyalgia

Fibromyalgia is a chronic syndrome characterized by widespread musculoskeletal pain, fatigue, sleep disturbances, and functional impairment, which significantly affects quality of life. Physical exercise is considered one of the most effective non-pharmacological interventions for the management of this condition; however, uncertainty remains regarding the most appropriate type, intensity, and frequency of exercise for different patient profiles. The aim of this study is to analyze the effects of a microdoses isokinetic exercise program on physical condition, perceived pain, inflammatory profile and quality of life in women diagnosed with fibromyalgia.

Physical exercise is one of the non-pharmacological treatments with the strongest evidence and effectiveness in the management of fibromyalgia, as it has been shown to improve muscle strength and, consequently, patients' quality of life. One of the main limitations in this population is low adherence to traditional exercise programs due to chronic pain. Microdoses exercise training emerges as an alternative approach, based on the principle of the minimum effective dose. To implement this intervention, the training program will be conducted using isokinetic exercise, which allows precise control of movement velocity and joint position to ensure safe conditions. Accordingly, the aim of the present study is to evaluate the effects of an isokinetic exercise microdosing program in women with fibromyalgia over an 8-week intervention period.

Inclusion Criteria:

• Women aged ≥ 18 years diagnosed with fibromyalgia according to current clinical criteria.
• Clinical and pharmacological stability during the weeks prior to participation in the study.
• Ability to perform supervised exercise and to complete the assessments.
• Written informed consent.

Exclusion Criteria:

• Cardiovascular, neurologic, musculoskeletal or systemic pathology that contraindicate the performance of exercise.
• Significant change in pharmacological treatment during the period immediately preceding the study.
• Any condition that, in clinical judgement, prevents them from following the protocol safely.